ICON Public Limited Company

ICLR

IE0005711209

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-05 pm EST			5-day change	1st Jan Change
185.87 ^USD	+0.05%		+1.21%	-11.37%

Dec. 02	Icon survey reveals increasing clinical trial startup delays	RE
Dec. 02	Icon plc Announces Results of Its Latest Industry Survey	CI

Jefferies Downgrades ICON to Hold From Buy, $175 Price Target

Published on 09/09/2025 at 07:14 am EDT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about ICON Public Limited Company

Dec. 02	Icon survey reveals increasing clinical trial startup delays	RE
Dec. 02	Icon plc Announces Results of Its Latest Industry Survey	CI
Nov. 20	ICON Public Limited Company Presents at Jefferies London Healthcare Conference 2025, Nov-19-2025 09:00 AM
Nov. 13	BMO Capital Initiates Coverage on ICON With Market Perform Rating, $175 Price Target	MT
Oct. 24	Truist Trims Price Target on ICON PLC to $231 From $234, Keeps Buy Rating	MT
Oct. 24	Deutsche Bank Trims Price Target on ICON PLC to $205 From $210, Keeps Buy Rating	MT
Oct. 23	ICON Public Limited Company, Q3 2025 Earnings Call, Oct 23, 2025
Oct. 22	ICON Q3 Adjusted Earnings Decline, Revenue Rises	MT
Oct. 22	Earnings Flash (ICLR) ICON plc Reports Q3 Revenue $2.04B, vs. FactSet Est of $1.98B	MT
Oct. 22	Earnings Flash (ICLR) ICON plc Posts Q3 Adjusted EPS $3.31 per Share	MT
Oct. 22	ICON Public Limited Company Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Oct. 22	Tranche Update on ICON Public Limited Company's Equity Buyback Plan announced on February 19, 2025.	CI
Oct. 22	ICON Public Limited Company updates Earnings Guidance for Full Year 2025	CI
Oct. 22	Icon plc Reports Goodwill Impairment for the Third Quarter Ended September 30, 2025	CI
Oct. 20	BofA Adjusts Price Target on ICON to $215 From $220	MT
Sep. 21	ICON Public Limited Company(NasdaqGS:ICLR) dropped from FTSE All-World Index	CI
Sep. 12	Analyst recommendations: Applovin, Casey’s General Stores, Ralph Lauren, Medpace Holdings, Air Products & Chemicals...
Sep. 09	ICON Shares Decline After Jefferies Downgrade	MT
Sep. 09	Jefferies Downgrades ICON to Hold From Buy, $175 Price Target	MT
Sep. 04	ICON plc Announces CEO Changes, Effective October 1, 2025	CI
Sep. 04	ICON plc Appoints Barry Balfe to the Board	CI
Sep. 04	Icon confirms no change in FY 2025 financial guidance	RE
Sep. 04	Icon CEO Steve Cutler to Retire; Barry Balfe to Take Reins	DJ
Sep. 04	Icon Promotes COO Barry Balfe to CEO Role	MT
Sep. 03	ICON Shares Rise After Rothschild & Co Redburn Upgrade	MT

Chart ICON Public Limited Company

Duration

Period

ICLR: Dynamic Chart

ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.

Employees

39,800

Sector

Biotechnology & Medical Research

Calendar

Feb. 24 - Q4 2025 Earnings Release (Projected)

More about the company